Research programme: therapeutic autoantibodies - Sengenics
Alternative Names: Autoantibody-based therapeuticsLatest Information Update: 28 Nov 2023
At a glance
- Originator Sengenics
- Class Antibodies; Antiparkinsonians; Antirheumatics; Behavioural disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autistic disorder; Parkinson's disease; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for research development in Autistic-disorder in Singapore (Parenteral)
- 28 Nov 2023 No recent reports of development identified for research development in Parkinson's-disease in Singapore (Parenteral)
- 28 Nov 2023 No recent reports of development identified for research development in Rheumatoid-arthritis in Singapore (Parenteral)